Bacteria that metabolize phenylacetate through mandelate

ABSTRACT

Bacteria that metabolize phenylacetate along a mandelate-to-cis,cis-muconate pathway are disclosed. Bacteria that express the pathway for metabolizing phenylacetate through a mandelate intermediate can be isolated reproducibly by first selecting bacteria that can utilize both L-phenylalanine and mandelate as the sole carbon source and then blocking alternate pathways for the degradation of L-phenylalanine. The activity of selected enzymes along the mandelate-to-cis,cis-muconate pathway can be blocked in these bacteria to effect the accumulation of selected intermediates.

BACKGROUND OF THE INVENTION

The present invention relates to bacteria that metabolize phenylacetatevia a mandelate pathway. More particularly, the present inventionrelates to a new group of bacteria characterized by an ability toproduce valuable compounds, including natural benzaldehyde, mandelate,benzyl alcohol, benzoate and cis,cis-muconic acid, which correspond tovarious intermediates along the aforesaid pathway.

A major use of benzaldehyde is as an ingredient in natural cherryflavors. An undesirable feature of the known processes for preparingbenzaldehyde from products like apricot kernels or reground press cake,as disclosed in U.S. Pat. No. 1,416,128, is that toxic hydrocyanic acid,along with benzaldehyde, is produced which must be separated completelyfrom the benzaldehyde. U.S. Pat. Nos. 4,617,419, and 4,673,766, disclosethe production of benzaldehyde from cinnamaldehyde according to aretro-aldol reaction, without production of toxic side products. But thedisclosed process requires a source of cinnamaldehyde, which may have tobe distilled or extracted prior to reaction.

A living organism that degrades a carbohydrate feedstock, orL-phenylalanine along a catabolic pathway having a benzaldehydeintermediate could provide a source for the production of naturalbenzaldehyde. Earlier studies have suggested that pathways for thedegradation of L-phenylalanine and phenylacetate along a mandelatepathway may occur in certain insects (Towers et al. (1972) Can. J. Zool.50(7): 1047-1050), micro-algae (Landymore et al. (1978) Phycologia17(3); 319-328), and fungi (Hockenhull et al. (1952) Biochem. J. 50:605-609 and Bioprocessing Technology (1987) 9(11): 2-3).

However, it was generally understood heretofore that bacteria could notmetabolize phenylacetate via a mandelate pathway, thereby to produce adesired intermediate like benzaldehyde. In this regard, the phrase"mandelate pathway" refers to that series of enzymatic degradations thatconverts mandelate to cis,cis-muconic acid. Intermediates of thedegradation include benzoylformate, benzaldehyde, benzoate and catechol.In accordance with standard terminology, the names used to refer to acidintermediates reflect their actual form in vivo (i.e., in solution),thus mandelic acid is referred to as mandelate.

Such a pathway is known to exist in both Pseudomonas (e.g., Stevenson etal. (1964) Biochem. J. 96: 354-362) and Acinetobacter calcoaceticus NCIB8250 (e.g., Cook et al. (1975) J. Gen. Microbiol. 91: 325-337), but itis only revealed when the bacteria are provided with feedstock in theform of mandelate or some other intermediate further along the pathway.Mandelate or benzoylformate are not readily available as naturalproducts. These and other intermediates are also too expensive to be ofuse as feedstocks in a commercial process for subsequent intermediates.

One early study tested the ability of a wide range of aromaticcompounds, both metabolizable and nonmetabolizable, to induce enzymes ofthe mandelate pathway. (Hegeman (1966) J. Bacteriol. 91(3): 1140-1154).Phenylacetate and phenylpyruvate, both possible degradationintermediates of L-phenylalanine, were among the many compounds testedand were shown to induce activities for mandelate dehydrogenase andbenzoylformate decarboxylase. But the link which allowed conversion ofphenylacetate to mandelate was completely unknown, and availablebiochemical evidence shows that L-phenylalanine and phenylacetate arenot metabolized through catechol to ketoadipate (Wheelis and Stanier(1970) Genetics 66: 245-266).

Consequently, the conversion of phenylacetate to mandelate by bacterialaction has been considered infeasible heretofore, even though expressionof such a pathway in bacteria could, in principle, enable theaccumulation of valuable chemical compounds as intermediates, forexample, of microbially mediated L-phenylalanine degradation.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide meanswhereby phenylacetate can be converted via bacteria to a usefulintermediate along the mandelate pathway.

It is a further object of the present invention to provide a bacteriaculture having the capability of metabolizing a carbohydrate feedstockor L-phenylalanine through a mandelate intermediate to accumulatedifferent mandelate-pathway intermediates.

It is yet another object of the invention to provide naturalbenzaldehyde from benzoylformate produced by a mutant bacterium with theability to metabolize L-phenylalanine through a mandelate intermediate.

In accomplishing the foregoing objects, there has been provided, inaccordance with one aspect of the present invention, a microbial cultureconsisting essentially of bacteria capable of metabolizing phenylacetatethrough a mandelate intermediate as shown in FIG. 1. In a preferredembodiment, the microbial culture contains at least some bacterial cellsthat lack active benzoylformate decarboxylase enzyme and, hence,accumulate the mandelate-pathway intermediate benzoylformate.

In accordance with another aspect of the invention, a process isprovided for isolating a bacterium which expresses a pathway formetabolizing phenylacetate through a mandelate intermediate, comprisingthe steps of mutating bacteria that can metabolize phenylalanine andmandelate, and then selecting from the mutated bacteria cells in whichthe routes of L-phenylalanine degradation other than aphenylacetate-to-mandelate pathway are blocked. A preferred method ofblocking the alternate pathways is by transposon mutagenesis. In onepreferred embodiment, the samples to be cultured are collected from anecological site that is exposed to a high concentration ofL-phenylalanine.

In accordance with yet another aspect of the invention, a process isprovided for the production of natural benzaldehyde in which bacterialbenzoylformate decarboxylase is added to benzoylformate.

Other objects, features and advantages of the present invention willbecome apparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples, while indicating preferred embodiments of the invention, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a composite diagram showing, inter alia, the aerobiccatabolism of L-phenylalanine in bacteria.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It has been discovered that a number of commercially valuable compounds,including natural benzaldehyde, mandelate, benzyl alcohol, benzoate andcis,cis-muconic acid, can be produced via bacterial fermentation byexploiting a metabolic pathway previously thought not to be expressed inbacteria. This pathway, shown diagrammatically in the solid block inFIG. 1, has been found in a range of bacterial strains that can beobtained reproducibly, in accordance with the present invention, as asubset of the group of bacteria characterized by an ability to grow onboth mandelate and L-phenylalanine, respectively, as the sole carbonsource.

This ability is believed widespread among the bacteria, such as theaerobic Pseudomanads, which are well characterized in this regard. SeeStanier et al. (1966) J. Gen. Microbiol. 43: 159-271. Pseudomonadstrains that grow both on D,L-mandelate and L-phenylalanine include P.aeuroenosa, P. putida, P. multivorans. and P. fluorescens.

In accordance with the present invention, an initial selection forbacteria that can utilize both L-phenylalanine and mandelate as the solecarbon source, followed by mutagenesis to block alternative routes forthe degradation of L-phenylalanine, results in bacteria which express apathway for the conversion of phenylacetate to mandelate. In a preferredembodiment, the selection prior to mutagenesis is followed by ascreening of the bacteria for an ability to grow on phenylacetate.

The bacteria of the present invention catabolize mandelate tocis,cis-muconate along the mandelate pathway, as described above. Theexact mechanism by which the phenylacetate-to-mandelate pathway isexpressed is not known, but such expression is obtained reproduciblywhen alternate routes of phenylacetate degradation are blocked.

In bacteria the established route of phenylacetate degradation is one ofthe ring-hydroxylation pathways, shown in the dotted block in FIG. 1.Bacteria that express a pathway for the conversion of phenylalanine tomandelate are obtained by blocking the ring-hydroxylation route(s)through mutagenesis. Certain bacteria can also metabolize phenylalanineto produce tyrosine. It is not necessary to block this latter pathway inorder to get expression of the phenylalanine-to-mandelate conversion.Furthermore, the phenylalanine to tyrosine pathway has been identifiedin some strains as a slow-growth pathway that does not greatly diminishthe production of mandelate intermediates from phenylalanine inaccordance with the present invention. To optimize production ofintermediates of the mandelate pathway, however, it is preferable thatthis alternative route also be blocked. Blocking the mandelate pathwayat specific points is accomplished by further mutagenesis, allowingselected intermediates of commercial importance to be produced.

Mutagenesis can be carried out by any of several well-known techniques,such as by transposon insertion or by treatment with a known mutagenicagent like ethane methyl sulfonate, nitrosoguanidine or ultravioletradiation. Alternatively, mutant alleles can be shifted among variousmutant strains by use of a suitable transducing phage. See, e.g.,Holloway et (1979) Microbiological Reviews 43: 73-102, and Ledoux (ed.),INFORMATIVE MOLECULES IN BIOLOGICAL SYSTEMS 223-33 (Ho])and press 1971),the contents of which are hereby incorporated by reference.

After mutagenesis, in accordance with the present invention,characterization of the mutation can be effected by testing the strainsfor growth on intermediates of L-phenylalanine degradation. By way ofexample, if a strain of bacteria is tested for growth on theintermediates of the mandelate pathway and exhibits growth onbenzoylformate, but not on mandelate, the strain is characterized ashaving a mutation affecting mandelate dehydrogenase activity. Thedesired mutation is one affecting the phenylacetic acid hydroxylaseactivity used by the cell. This mutation blocks the normalring-hydroxylation route of phenylacetate degradation resulting instrains that cannot grow on phenylacetate. It is blockage of this normalroute that results in expression by these strains of the pathway fordegradation of phenylacetate through a mandelate intermediate.

One preferred mutation method in this regard is transposon insertion.Transposons are DNA segments that have the ability to move as a unit, ina more or less random fashion, from one genetic locus to another. See,e.g., Lewin, GENES 589-608 (John Wiley & Sons 1983). Various transposonsare commercially available, e.g., from the E. coli Genetic Stocks Center(Yale University School of Medicine, New Haven, Conn.) and from theAmerican Type Culture Collection (ATCC) in Rockville, Md.

Donor cells carrying a plasmid are used to move transposons into targetcells via conjugation. At a frequency of approximately 1×10⁻⁸, atransposon copy becomes inserted, before loss of the plasmid can occur,into a chromosome of a recipient organism. The transposon carries amarker, e.g., for antibiotic resistance, so that insertion can bedetected. It is also necessary to have a means of selecting against thedonor cells. Insertion of a transposon within a gene can result in acomplete loss of gene function. If inserted within a structural gene, atransposon may inactivate the specific enzyme activity encoded by thegene, resulting in mutants that are blocked in the degradativebiochemical pathway(s) comprising that enzyme.

The advantage of transposon mutagenesis is that, while the frequency ofmutation is high, the probability of double events is extremely smalland every clone containing the marker which arises in a translocationexperiment is one identified as having suffered a single mutationalevent. See, e.g., Kleckner et al. (1977) J. Mol. Biol. 116: 125-150.

After a strain is obtained which converts phenylacetate to mandelate,further manipulations can be used both to increase the endogenousproduction of L-phenylalanine and to enhance the degradation ofL-phenylalanine.

In the former context, deregulation of the L-phenylalanine syntheticpathway results in a microorganism that overproduces L-phenylalanine.This allows the use of inexpensive, carbohydrate-based feedstocks, suchas molasses, hydrolyzed or liquified starch compositions, andhigh-fructose corn syrup, as a starting material for the manufacture ofdesirable compounds.

Bacterial strains which overproduce amino acids have commonly beenproduced by the use of analogs, e.g., halogenated amino acids, thatmimic the regulatory effect of the natural compound. See Gollub et al.(1973) J. Bacteriol. 115: 121-128, and Im & Pittard (1971) J. Bacteriol.106: 784-790, both incorporated herein by reference. These analogscannot be used by the cell, but do act as corepressors or feedbackinhibitors of enzymes responsible for amino acid biosynthesis. Thus, thecells are starved for required amino acids.

By selecting for cells able to grow in the presence of the analogs,strains with repressor mutations or feedback-resistant enzyme systemsare obtained. The lack of negative regulation in these cells results inincreased amino acid synthesis. By using multiple analogs, affectingdifferent regulatory enzymes for the synthetic pathway, furtherincreases in the production of the particular amino acid are possible.Bacteria according to the present invention which secrete greateramounts of L-phenylalanine have been selected by their resistance toboth 3 - fluorophenylalanine and 4-fluorophenylalanine.

Greater yields of L-phenylalanine can be achieved by combining analogresistance with auxotrophic mutations. See Fawcett et al. (1976)Biochem. J. 157: 651. In bacteria the three aromatic amino acids(tyrosine, L-phenylalanine and tryptophan) are usually formed from acommon intermediate, chorismic acid. Blocking the synthetic routes totyrosine and tryptophan by mutation can result in additionalintercellular amounts of L-phenylalanine. In these auxotrophs,starvation for the required amino acids should cause constitutiveinduction of the chorismate pathway synthetic enzymes, leading toincreased production of L-phenylalanine. This strategy has been utilizedfor the production of L-phenylalanine in Corynebacterium (Hagino andNakayama (1974) Agric. Biol. Chem. 38: 157).

Genetic modifications can also be made to increase the L-phenylalaninedegradative capability by elevating the rates of subsequent degradativesteps, thus reducing the accumulation and possible secretion ofL-phenylalanine. This draining of the L-phenylalanine synthetic pathwayshould also alleviate repression and feedback inhibition of syntheticenzymes, as discussed above, leading to increased yield.

The final step in the synthetic pathway from chorismic acid toL-phenylalanine utilizes a transaminase reaction to form L-phenylalaninefrom phenylpyruvate. The reverse reaction is the first stage ofL-phenylalanine degradation in the desired pathway. In some strainsanother enzyme, L-amino acid dehydrogenase or phenylalanine deaminase,will also carry out this reaction. If the transaminase and dehydrogenaseactivity is removed by mutation, phenylpyruvate formed from chorismicacid may be used in production of mandelate pathway intermediates.Bypassing the synthesis of L-phenylalanine in this way allows externalregulation of L-phenylalanine availability. By causing L-phenylalaninestarvation at the desired time, increased formation of phenylpyruvate isinduced. The phenylpyruvate is metabolized via mandelate, resulting inincreased product formation. Starvation for L-phenylalanine alsoreleases any remaining repression, feedback inhibition, and attenuationthat moderates the carbon flow in the L-phenylalanine pathway.

The second enzyme of the desired pathway, phenylpyruvate decarboxylase,can also be manipulated to improve L-phenylalanine degradation. Thisenzyme has been identified as the rate-limiting step in the flow ofcarbon from L-phenylalanine to L-mandelate. Because the decarboxylationis essentially irreversible, increasing this enzyme activity willgreatly shift the equilibrium of earlier reactions towards completion.Mutants with a more proficient phenylpyruvate decarboxylase can beidentified by their larger colony size on L-phenylalanine agar aftertreatment with mutagens. Alternatively, continuous dilution of culturesgrowing on L-phenylalanine broth can be used to select for the morerapidly growing mutants. It has been discovered that some phenylalanineanalog resistant mutants have increased phenylpyruvate decarboxylaseenzyme activity.

Pursuant to the present invention, L-phenylalanine or carbohydrate-basedfeedstocks can be used as the feedstock in a fermentation process inorder to produce the desired product in high purity economically andnaturally. In this context, "fermentation" is used broadly to refer toany controlled microbial action by which useful products are obtainedfrom the substrate(s) of that action. In accordance with the presentinvention, fermentation can be carried out in a stirred-tank reactor, aclosed cylindrical tank containing agitators, baffles, heat exchangecoils, and automatic controls for temperature, air flow, pressure, pH,and foaming. A fermenter of this sort would be charged with essentialnutrients and the feedstock, sterilized and inoculated with a rapidlygrowing culture consisting essentially of bacteria mutationally blockedfor the enzymatic degradation of the desired intermediate. Othermicrobial cells may be present, so long as they do not interfere withthe production of the desired intermediate by bacteria within thepresent invention.

Continuous culture can increase fermenter productivity by eliminatingthe downtime of batch cultures. However, it is difficult to maintainsterility in large scale continuous cultures. Accordingly, batchfermentations which utilize the bacteria of the present invention arepreferred.

Commercially valuable compounds along the mandelate pathway includecis,cis-muconic acid, which is useful as a plastic monomer (see U.S.Pat. Nos. 4,588,688, 4,555,107 and 4,535,059), as well as benzaldehydeand benzyl alcohol, both useful flavoring constituents. Another pathwayintermediate, benzoate, is useful as a natural preservative. Mandelate,which is useful as a drug precursor (see U.S. Pat. Nos. 3,957,758 and4,391,826), is also an intermediate in the pathway. In order toaccumulate a particular intermediate, mutagenesis is employed, asdescribed above, to block activity of the enzyme that converts theintermediate of interest to the next intermediate on the pathway. Forexample, a block of muconate lactonizing enzyme results in anaccumulation of cis,cis-muconate.

In some cases, it may be desirable to stop the pathway at a step earlierthan the desired intermediate, e.g., if the intermediate accumulated istoxic to the bacteria, as is the case with benzaldehyde. In a processfor producing natural benzaldehyde, it is desirable to accumulatebenzoylformate rather than benzaldehyde because aldehydes are generallyvery reactive toward sulfhydryl and amino groups in enzymes (protein)and tend rapidly to inactivate their activity. Benzaldehyde, inparticular, is an effective biocide at concentrations much lower thanwould be necessary for economical production. By stopping the pathway atbenzoylformate, pursuant to the present invention, and then convertingthe benzoylformate in an enzymatic reactor with benzoylformatedecarboxylase, toxic effects on the bacteria can be avoided.

Surprisingly, benzoylformate decarboxylase enzyme obtained from bacteriathat can metabolize mandelate to benzoic acid (see FIG. 1) has beenfound to remain active and operate at favorable rates even in thepresence of saturating concentrations of benzaldehyde (the solubility ofbenzaldehyde in water is 0.33 g per 100 ml). Although any bacteriumhaving the mandelate-to-benzoic pathway can be used in this regard,bacteria that have been selected for their ability to grow on bothmandelate and phenylalanine, as described previously, are preferred as asource for the benzaldehyde-resistant benzoylformate decarboxylase(hereafter "bacterial benzoylformate decarboxylase"). Alternatively,conventional recombinant-DNA techniques can be applied to isolate andclone from suitable bacteria the gene coding for the aldehyde-resistantdecarboxylase, and that gene can be used to transform E. coli or someother microbial strain from which the enzyme is then derived.Established genetic manipulations, such as an increase in gene copynumber or promoter fusions, could also be employed to effect anoverproduction of bacterial benzoylformate decarboxylase.

Even in emulsions in which the concentration of benzaldehyde is 5%,bacterial benzoylformate decarboxylase retains significant activity.This is highly unexpected since aldehydes are generally very reactivetoward sulfhydryl and amino groups of proteins, and hence tend rapidlyto inactivate enzymes. Accordingly, bacterial benzoylformatedecarboxylase can be employed, pursuant to the present invention, inconverting benzoylformate into benzaldehyde. For example, the doublemutant of a strain expressing the desired pathway in which the activityof benzoylformate decarboxylase has been blocked will accumulatebenzoylformate when grown on L-phenylalanine. The accumulatedbenzoylformate can be converted to benzaldehyde by the action ofbacterial benzoylformate decarboxylase activity in an enzymatic reactor.

As indicated below, bacterial benzoylformate decarboxylase was partiallypurified from soil isolates according to Hegeman, METHODS IN ENZYMOLOGY88: 674, the contents of which are hereby incorporated by reference. Solong as the activity of the enzyme is not significantly affected,however, the procedure by which the bacterial benzoylformatedecarboxylase is obtained is not critical. For large-scale production,for example, several other preparatory methods could be used. Forexample, whole cells could be used, optionally with a 55° C. heattreatment to inactivate benzaldehyde dehydrogenase. Alternatively, thecells could first by lysed (in a continuous-flow homogenizer, forexample), followed by a heat treatment of the lysate at 55° C. for tenminutes and filtration to remove particulate and coagulated denaturedprotein. Filtration could be through a celite-precoated rotary drumvacuum filter or an ultrafiltration device with a 150,000 molecularweight cutoff.

Bacterial benzoylformate decarboxylase was obtained, pursuant to Hegemansupra, using bacterial cells grown on mandelate or benzoylformate, whichcells had been isolated from phenylalanine-rich soil via selection forgrowth on L-phenylalanine and mandelate, respectively (see Example 1below). The bacterial benzoylformate decarboxylase produced by thesecells, which were typed as P. putida, was used in a bioreactor toconvert benzoylformate to benzaldehyde. Biochemical assays have alsoshown that a bacterial mutant lacking the ability to use phenylacetate(see Example 4 below) has a greatly enhanced activity of this enzyme.Such a mutant could therefore also serve as a source of increasedamounts of bacterial benzoylformate decarboxylase.

The present invention is further described below by reference to thefollowing illustrative examples.

EXAMPLE 1 Isolating Starting Material from the Soil.

Specimens were collected from a site where spillage from the large-scaleproduction of L-phenylalanine had contaminated the surrounding soil.Twenty grams of these soil samples were inoculated into four hundredmilliliters of minimal culture media which contained a sodium/potassiumphosphate buffer, an inorganic nitrogen source, and essential mineralsalts. Carbon was supplied as 0.1% (w/v) glucose and 0.2%L-phenylalanine. Nystatin was added to 50 micrograms/ml to controlfungal growth. Cultures were incubated at 34° C. with strong aeration byshaking at 400 rpm in 2 liter baffled flasks. After 24 hours, theculture broths were passed through a coarse milk filter to remove debrisand divided 1:2 into fresh medium. Following an additional 24 hourincubation, cultures were filtered through Whatman No. 4 paper to clearfine particles and diluted 1:5 into minimal medium with 0.1%L-phenylalanine, 0.1% mandelic acid, and 0.05% glucose.

At daily intervals cultures were split 1:5 into fresh medium alternatingbetween L-phenylalanine and mandelate as growth substrate. This schedulewas utilized to enrich the cultures for organisms able to efficientlydegrade both compounds, at rates required for an industrial process.

From day #7 until the end of the enrichment at day #17, samples from thecultures were diluted and plated on a rich agar medium to isolatecandidate organisms. Individual colonies were then tested for growth onagar medium containing L-phenylalanine or mandelate to determine theeffectiveness of the enrichment procedure. Microorganisms which grew onboth substrates were preserved for further screening.

Isolates which exhibited growth on L-phenylalanine and mandelate werenext assayed for the ability to utilize other proposed intermediates ofL-phenylalanine degradation, including phenylacetate. Of the original 42candidates isolated, 6 showed sufficient growth on substrates of thedesired pathway, and little or no growth initially on compounds whichwould indicate an alternative degradative route (i.e., little or nogrowth on ring-hydroxylated intermediates). However, when grown onphenylacetate, the ability to grow on ring-hydroxylated intermediateswas induced. Thus, selection for individual isolates which do not growon the ring-hydroxylated intermediates is ineffective in selecting astrain which will directly express the phenylacetate-to-mandelateconversion.

EXAMPLE 2 Mutating the Starting Material to Block the Alternate Route ofPhenylacetate Degradation

The six selected strains, all gram-negative rods, were next examined forthe ability to apply transposon mutagenesis methods in order to developa production strain which was blocked for the passage of phenylacetateto the ring-hydroxylation pathway.

E. coli strain NC967 carries a narrow-host-range plasmid which can beused to move a transposon (Tn10) into related bacteria via conjugation.See, e.g., Figurski et al (1979) Proc. Nat'l. Acad. Sci. USA 76:1648-1652, the contents of which are hereby incorporated by reference.The vehicle for transposon transfer is plasmid pRK2013::Tn10.

Cells from the E. coli donor strain were mated with each of the selectedstrains by plating a 1:1 mixture of cells on solid media. After 12-18hours incubation to allow plasmid transfer to occur, the cells werewashed and replated on minimal glucose agar containing tetracycline toselect for transconjugates. The E. coli donor cells are unable to growon these plates due to a requirement for amino acid supplements. Thus,only recipient cells that have incorporated a transposon into their .chromosome (becoming tetracycline resistant) will form colonies.

Of the six strains selected on the basis of growth on the desiredsubstrates, two were found to mate with E. coli NC967 and accept thetransposon efficiently. One of these two strains was subsequentlyidentified as P. putida by the American Type Culture Collection (ATCC),Rockville, Md. This strain has been deposited with the ATCC and has beendesignated as ATCC No. 55012. The identification by the ATCC showed thefollowing:

    ______________________________________                                                       P. putida                                                                            ATCC No.                                                ______________________________________                                        Motility         +        +                                                   Polar            +        +                                                   multitrichous                                                                 flagella                                                                      Aerobic          +        +                                                   metabolism                                                                    Fluorescent      V*       +                                                   pigment                                                                       Denitrification  -        -                                                   Gelatin          -        -                                                   hydrolysis                                                                    Growth at 42° C.                                                                        -        -                                                   Moellers medium                                                               lysine           -        -                                                   arginine         +        +                                                   ornithine        -        -                                                   Utilization as                                                                sole carbon source                                                            D-glucose        +        +                                                   benzylamide      +        +                                                   glycine          +        +                                                   trehalose        -        -                                                   i-inositol       -        -                                                   geraniol         -        -                                                   ______________________________________                                         *V = variable (11-89% of P. putida strains test positive for this             characteristic.                                                          

EXAMPLE 3 Identifying Mutants and Selecting Mutants Blocked for theAlternative Route of Phenylacetate Degradation

Colonies which had accepted the transposon were transferred to agarcontaining pathway intermediates to identify enzyme deficient mutants.By means of this mutation protocol, several mutant derivatives of one ofthe isolates, were identified and characterized.

The desired mutant was produced with Tn10. This mutant lacked only theability to utilize phenylacetate as a carbon source and was subjected toan analysis of its L-phenylalanine degradation. Cell-free culture mediumfrom high-density cultures growing on L-phenylalanine was acidified andextracted twice with ethyl ether. The ether was evaporated and the driedextracts were resuspended in aqueous 20% ethanol and separated by HPLCusing a Bio-Rad HPX-87H HPLC column at 65° C. The mobile phase was 0.01N H₂ SO₄, 10% acetonitrile, at a flow rate of 0.6 ml/min. Elutedcompounds were detected by monitoring the absorbance at 205 nm.

Analysis of aromatic chemicals in culture broths revealed phenylacetatewas the major product accumulated when cells were grown onL-phenylalanine. In similar studies with broth containing phenylacetate,the phenylacetate was not degraded. Previous experiments with thewild-type cells had shown that a hydroxylation of phenylacetate to formthe 2-hydroxy derivative was the next degradative step. This indicatedthat the phenylacetate 2-hydroxylase enzyme activity had beeninactivated by insertion of Tn10.

Other mutants were produced by transposon insertion. Mutations can betransferred from these mutants, via a transducing phage according toconventional methodology, into strains expressing the desired mandelatepathway in order to produce strains which concentrate desiredintermediates.

For example, one such mutant was identified by its slow growth on agarcontaining D/L-mandelate, benzoylformate, or 1-phenyl-1,2-hydroxyethane(diol) as the sole carbon source. Growth rates comparable to those ofthe wild type isolate are seen when this mutant is grown on benzaldehydeor benzoic acid.

To identify the nature of the metabolic defect in this mutant standardmethods were used for the assay of benzoylformate decarboxylase. See,e.g., Gunsalus et al. (1953) J. Bacteriol. 66: 548, the contents ofwhich are hereby incorporated by reference. This enzyme convertsbenzoylformate to benzaldehyde and CO₂. Crude cell extracts from themutant were found to have a decreased benzoylformate decarboxylasespecific activity relative to cell extracts from the wild type. Thisindicated that partial loss of benzoylformate decarboxylase function hadresulted from the insertion of Tn10. Accordingly, transfer of thismutation would result in partial loss of benzoylformate decarboxylasefunction in the recipient strain.

EXAMPLE 4 Expression of the Mandelate Pathway in Bacteria Blocked forthe Alternative Route of Phenylacetate Degradation

The mutant which lacked the ability to utilize phenylacetate was grownon media containing phenylacetate and produced at a low frequency somecells which spontaneously regained the ability to degrade phenylacetate.These cells remained tetracycline resistant, suggesting that there wasnot excision and loss of Tn10. When culture broth from one suchspontaneously-growing mutant was subjected to analysis, via highpressure liquid chromatography (HPLC) after growth on phenylacetate,different intermediates accumulated than with wild-type cells grownunder the same conditions. Mandelate and benzoate were identified asmetabolic intermediates of these mutants based on UV spectra and HPLCretention times.

In the wild-type cells the conversion of phenylacetate to mandelateapparently proceeds at insignificant rates. Only by blocking the normalroute of phenylacetate degradation are strains readily identified thatare characterized by the ability to rapidly metabolize phenylacetatethrough a mandelate pathway.

EXAMPLE 5 Mutating with a Second Transposon to Produce Double Mutants

After a strain which degrades phenylacetate by the mandelate pathway hasbeen isolated, additional metabolic blocks may be introduced by theselective inactivation of degradative enzymes. The additional metabolicblocks allow degradation along the mandelate pathway to be "stopped" atvarious points, resulting in accumulation of the intermediate just priorto the enzymatic step blocked.

By way of example, double mutants of the mutant which lacked the abilityto utilize phenylacetate have been obtained by the use of anothertransposon delivery system as described in Simon et al (1983)Bio/Technology 7(3): 784-791, the contents of which are herebyincorporated by reference. Although these double mutants were producedfrom the mutant which lacked the ability to utilize phenylacetate (astrain which did not express the desired phenylacetate-to-mandelatepathway) the same technique could be used to produce double mutants of amutant strain that does express the phenylacetate-to-mandelate pathway.Thus, strains can be developed which are blocked at any desiredintermediate.

Matings with the second E. coli donor strain, SM10(pSup2021), have beenperformed to convey Tn5 into single mutant strains. Transposon insertionwas selected on the basis of resistance to kanamycin. Identification ofdouble mutant strains was performed using techniques similar to thosedescribed above for identification of single mutants.

One of the mutant strains accumulated catechol when grown on benzoicacid. Thus, it was characterized as having a partial block of catechol1,2-dioxygenase activity. Another mutant strain completely lost activityof an as yet unidentified enzyme resulting in a total loss of growth onthe compounds of the mandelate pathway. The strain did not grow on themandelate pathway intermediates, D/L-mandelate, benzoylformate,benzaldehyde, and benzoate, or the similar compounds, 4-hydroxybenzoate, and protocatechuate. Unlike the mutants that express thephenylalanine-to-mandelate conversion which spontaneously arise frommutants lacking the ability to utilize phenylacetate, this double mutantstrain never yielded progeny with the ability to grow on phenylacetate.This provided further confirmation that the strain of Example 4 grew asa result of activation of the phenylacetate-to-mandelate enzymaticconversion.

As previously noted, an alternative method of producing double mutantsfrom a mutant expressing the phenylacetate-to-mandelate conversion wouldbe to move mutant alleles previously created in strains which do notexpress the desired pathway into a strain expressing the desired pathwayby transduction with a suitable transducing phage. For example, thetransduction of the deficient allele from the above-identified mutant inwhich benzoylformate decarboxylase (see Example 3) is blocked into astrain expressing the desired pathway would result in a strain thataccumulates benzoylformate when grown on L-phenylalanine. Benzoylformateis an important precursor for the production of natural benzaldehyde.

EXAMPLE 6 Isolation of Benzoylformate Decarboxylase-Deficient Mutants

An overnight culture of the bacteria of Example 4 grown in YPD broth wascentrifuged, washed, and resuspended in ml saline. Final cell densityhad an absorbance at 600 nm of 0.7, corresponding to 4×10⁷ cells/ml.Cells were irradiated on a platform agitator approximately 30 cm from agermicidal UV lamp. Exposure for 20 seconds was found to reproducibilitykill 99.5% of the cells, near the optimum ratio for mutagenesis.

Indicator plates containing were used for the detection of mutants. Thisprocedure provides a convenient and sensitive screening method forisolating blocked mutants. Diluting the irradiated cells 1:50 withsaline and spreading 80 μl of this suspension yielded 600-700 survivingcolonies on each 150 mm petri dish. Growth on tetrazolium plates(Bochner and Savageau (1977) Appl. Environ. Microbiol. 33(2):434-444)supplemented with 1 g/L Dmandelic acid was used to identify cellsdefective in enzymes of the mandelate pathway. In addition to substrate,these plates contained 7 g/L K₂ HPO₄, 3 g/L KH₂ PO₄, 0.1 g/L MgSO₄, 2g/L proteose peptone, 25 mg/L 2,3,5-triphenyl tetrazolium chloride and15 g/L agar. Several mutant colonies were identified by their lack oftetrazolium dye reduction, and were subjected to further screening.

Two mutant strains grew well on benzaldehyde and benzoic acid, but wereunable to grow on mandelic acid or benzoylformate. This phenotypeindicated a deficiency of the enzyme benzoylformate decarboxylase.Assays of benzoylformate decarboxylase activity in cell-free extractsshowed that these strains displayed reduced activity for this enzyme,relative to the parent strain.

Benzoylformic acid was identified as a product of phenylacetatemetabolism in one of the two strains through HPLC and spectrophotometricmethods. Additional mutations and refined biotransformation conditionscan improve the titer realized from use of this type of strain, andallow the efficient conversion from L-phenylalanine or a carbohydratestarting material.

EXAMPLE 7 Isolation of L-Phenylalanine Analog Resistant Mutants

Cells from an overnight culture of the bacteria of Example 4 were grownin 2 ml YPD broth, collected by centrifugation and diluted to 3×10⁷cells/mL (A₆₀₀ =0.5). One hundred microliters of this suspension wasplated onto a 100 mm petri dish of minimal media containing 1 g/Lglucose and allowed to absorb into the agar. Approximately 5 mg of4-fluoro L-phenylalanine, or 3-fluoro L-phenylalanine was placed in thecenter of the plate prior to incubation at 34° C. A cleared zone ofgrowth inhibition appeared around the analog after 48 hours. Resistantcolonies were detected in this cleared zone. Cells obtained from thisregion of the plates were preserved and later tested for theoverproduction of L-phenylalanine.

As an alternative method, the L-phenylalanine analogs were added at aconcentration of 10 mg/ml into minimal glucose media after the agar hadbeen autoclaved and partially cooled. Fifteen milliliters of this mediawere added to 100 mm plates. An edge of these plates was elevated duringhardening, causing the agar to harden at an angle. An equal volume ofminimal media containing no analog was subsequently poured over theprevious agar in each plate, and the dishes were placed on a levelsurface to cool. This procedure created a gradient of analogconcentration on which cells were plated as described above. In thiscase, mutant colonies were obtained from a cleared zone corresponding tothe higher analog concentrations.

Mutants isolated in these experiments were tested to determine if theiranalog resistance was manifested in an increased production ofL-phenylalanine. Cells were grown in minimal glucose broth media to latelog phase and then removed by centrifugation. Cell-free culture brothwas assayed for the presence of free amino acids using ninhydrinreagent, following the procedure of Moore (1968) J. Biol. Chem. 243:6281. Samples of the parent strain of Example 4 were prepared in anidentical manner for comparison.

Several of the isolates were found to secrete higher amounts ofninhydrin-reacting material relative to the parent strain which is notresistant to fluorinated L-phenylalanine.

EXAMPLE 8 Preparation of Benzaldehyde from Benzoylformate usingBacterial Benzoylformate Decarboxylase

Bacterial benzoylformate decarboxylase was used to produce benzaldehydefrom commercially available benzoylformate in a bioreactor. The totalreaction volume was 24 ml and comprised the following:

    ______________________________________                                        2.0 ml    0.1 M benzoylformate                                                0.8 ml    0.5 mg/ml thiamine pyrophosphate                                    16.0 ml   sodium phosphate buffer                                                       (0.1 M, pH = 6.0)                                                   0.8 ml    bacterial benzoylformate decarboxylase                              4.4 ml    H.sub.2 O                                                           ______________________________________                                    

The bacterial benzoylformate decarboxylase was obtained from soilisolates and was partially purified through Step 5 according to Hegeman,supra. The temperature was kept at 25° C. and the pH was maintained atthe pH of 6.0 by addition of sodium hydroxide. Nitrogen gas above thesurface of the liquid prevented oxidation of reaction products. Themixture was reacted with continuous stirring. After 24 hours thereaction mixture was extracted. The production of benzaldehyde wasconfirmed by HPLC analysis.

As will be evident to those skilled in the art, various modifications ofthe present invention can be made without departing from its spirit orscope. As previously mentioned, for example, proper selection ofbacteria produced in accordance with the present invention can allow acarbohydrate-based composition to replace L-phenylalanine as thefeedstock in the fermentation process. Moreover, as the commercialimportance of other intermediates along the mandelate pathway becomesapparent, suitable mutants blocked for production of the correspondingenzyme can be routinely produced pursuant to the present invention, toaccumulate these intermediates. In this regard, certain of the mutantstrains mentioned in the foregoing examples should be seen as merelyillustrative of strains that can be employed, as indicated above, tomake commercial use of the mandelate pathway. In accordance with thepresent invention, other strains can be produced that have a desiredphenotype and that are at least equally as useful in exploiting themandelate pathway.

What is claimed is:
 1. A biologically pure microbial culture consistingessentially of bacterial cells that can metabolize phenylacetate througha mandelate intermediate.
 2. A microbial culture as claimed in claim 1,wherein at least some of said bacterial cells lack active benzoylformatedecarboxylase enzyme.
 3. A microbial culture as claimed in claim 1,wherein at least some of said bacterial cells lack active muconatelactonizing enzyme.
 4. A biologically pure culture of bacterial cellsthat express a pathway for metabolizing phenylacetate through amandelate intermediate, said culture being the product of a processcomprising the steps of mutating bacteria that can metabolizephenylalanine and mandelate; and then selecting, from said bacteria,cells wherein routes of L-phenylalanine degradation other than aphenylacetate-to-mandelate pathway are blocked.
 5. A culture accordingto claim 4, wherein said mutating step comprises exposure to ultravioletradiation.
 6. A culture according to claim 4, additionally comprisingthe step of blocking the activity of at least one enzyme along saidpathway.
 7. A culture according to claim 6, wherein the activity of atleast one enzyme causing conversion of benzoylformate to benzaldehyde isblocked.
 8. A culture according to claim 4, wherein said process furthercomprises the step, prior to said mutating step, of collecting saidbacteria from an ecological site having exposure to a high concentrationof L-phenylalanine.
 9. A culture according to claim 4, wherein saidprocess further comprises the step, prior to said mutating step, ofselecting for bacteria that can metabolize phenylacetate.
 10. A processfor producing bacteria that express a pathway for metabolizingphenylacetate through a mandelate intermediate, comprising the steps ofmutating bacteria that can metabolize L-phenylalanine and mandelate; andthen selecting, from said bacteria, cells wherein routes ofL-phenylalanine degradation other than a phenylacetate-to-mandelatepathway are blocked.
 11. A process as claimed in claim 10, additionallycomprising the step, prior to said mutating step, of collecting saidbacteria from an ecological site having exposure to a high concentrationof L-phenylalanine.
 12. A process as claimed in claim 10, additionallycomprising the step, prior to said mutating step, of selecting forbacteria that can metabolize phenylacetate.